A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane–tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies

What is it about?

The World Health Organisation has identified novel treatment options for some carbapenem-resistant Gram-negative pathogens as being of the highest priority. High quality methodology for measuring this novel combination antibiotic in pharmacokinetic studies is essential to ensure effective treatment. Ceftolozane-tazobactam has potent bactericidal activity against the most difficult-to-treat multi-drug resistant and extensively drug resistant Gram-negative pathogens. The methodology presented here is the only method describing the simultaneous measurement of a novel and important antibiotic combination therapy in this range of matrices.

Featured Image